ClaimsPeople

Vinod Khosla

Vinod Khosla is a venture capitalist and founder of Khosla Ventures, and a co-founder of Sun Microsystems.

567 claims collected, 179 researched, 52 resolved. Report of 4 November 2026, method 0.1.0+c876030c.

Scores by kind of claim

Each kind of claim is scored on its own, out of 100: the share that held up, with the range it likely falls in. Fewer resolved claims give a wider range.

  • Factual claims

    Statements about the present or the past, checked against the record: did they hold up?

    72 64 80

    Medium confidence, 43 factual claims resolved. From 11 documents, 2007 to 2024; 19 documents sampled from 31 candidates found.

    Not scored: 44 unresolvable, 21 checkable only against their own records.

  • Predictions

    Statements about events outside the person's control, checked once they fell due: did they come true?

    58 40 75

    Low confidence, 9 predictions resolved. From 2 documents, 2007 to 2010; 19 documents sampled from 31 candidates found.

    Not scored: 46 unresolvable, 1 checkable only against their own records. 15 more fall due later.

    Does not yet allow for how likely each prediction was when made.

All types combined: 70 (likely 62 to 77, high confidence), from 52 claims: 43 factual claims, 9 predictions. It mixes kinds of claim in different proportions for different people, so compare people kind by kind.

Vinod Khosla's claims

25 claims

25 claims, sorted by newest said. Choose a claim to read it in full.
VerdictKindSaidClaimTopic
Mostly true Factual 9 Apr 2024 Andy Grove was an immigrant who founded a cutting-edge technology company in America. Factual · 9 Apr 2024 Technology
Mostly true Factual 9 Apr 2024 Vinod Khosla calls himself a "venture assistant", which used to annoy his former colleague John Doerr. Factual · 9 Apr 2024 Their own work or organisation
Mostly true Factual 13 Dec 2023 Autonomous driving in closed systems is now easy to do and to deploy. Factual · 13 Dec 2023 AI capabilities
Mostly true Factual 5 Dec 2021 People in counties that voted heavily for Donald Trump in the last presidential election have been nearly three times as likely to die from COVID-19. Factual · 5 Dec 2021 Biosecurity
Mostly true Factual 20 Oct 2021 GitLab's outcome produced massive financial returns for Khosla Ventures and other investors. Factual · 20 Oct 2021 Economics and markets
Mostly true Factual 14 Oct 2021 Soon after an earlier point in time, a Lehman analyst predicted Amazon (AMZN) would go bankrupt. Factual · 14 Oct 2021 Their own work or organisation
Mostly true Factual 29 Sep 2020 Ronald Reagan dropped the FCC requirements for balanced reporting. Factual · 29 Sep 2020 AI policy and governance
Mostly true Factual 5 Sep 2020 Khosla said Fox News had confirmed reporting that contradicted Donald Trump's statements in the preceding day or so. Factual · 5 Sep 2020 Other
Mostly true Factual 4 Sep 2020 The bradykinin hypothesis for Covid-19 suggests 10-plus potential treatments, many of which are already FDA approved. Factual · 4 Sep 2020 Biosecurity
Mostly true Factual 16 May 2019 Rubrik is younger than Cohesity and is growing much faster than Cohesity. Factual · 16 May 2019 Economics and markets
Mostly true Factual 14 Jan 2014 There is $51 billion remaining in DOE loan money. Factual · 14 Jan 2014 Economics and markets
Mostly true Factual 14 Jan 2014 The U.S. Department of Energy Loan Guarantee Program has created 55,000 new cleantech jobs. Factual · 14 Jan 2014 Economics and markets
Mostly true Factual 14 Jan 2014 A substantial portion of DOE loans is allocated to nuclear energy. Factual · 14 Jan 2014 Economics and markets
Mostly true Factual 14 Jan 2014 Oil prospecting has a failure rate greater than 55 percent. Factual · 14 Jan 2014 Technology
Mostly true Factual 14 Jan 2014 The U.S. DOE loan program has a 97% success rate. Factual · 14 Jan 2014 Economics and markets
Mostly true Factual 28 Sep 2007 Utilities are currently forced to take the power the subject was discussing (power he said nobody needs at night), which he described as really just a tax. Factual · 28 Sep 2007 AI policy and governance
Mostly true Factual 28 Sep 2007 Strong government signals in Europe have made a big difference in advancing renewables there. Factual · 28 Sep 2007 AI policy and governance
Mostly true Factual 28 Sep 2007 Geothermal power works extremely well in certain regions. Factual · 28 Sep 2007 Technology
Mostly true Factual 28 Sep 2007 Khosla said he believed there had been relatively little controversy over cellulosic ethanol, and that most of the controversy had focused on corn ethanol. Factual · 28 Sep 2007 Technology
Mostly true Prediction 28 Sep 2007 Pricing carbon and requiring carbon capture and sequestration would probably add about 2 cents per kilowatt hour to the cost of coal power, depending on the carbon price. Prediction · 28 Sep 2007 Technology
Mostly true Factual 28 Sep 2007 Khosla said he believed a massive amount of PR money was being funded by various oil interests, including oil companies and the American Petroleum Institute. Factual · 28 Sep 2007 Economics and markets
Mostly true Prediction 28 Sep 2007 Even if Germany switched completely to photovoltaics, climate change's trajectory will not change unless India and China also adopt them. Prediction · 28 Sep 2007 Technology
Mostly true Factual 28 Sep 2007 There are scientists who are not paid by anybody who believe climate change does not exist, though the speaker immediately added that "plenty" was a bit of a stretch. Factual · 28 Sep 2007 Science and research methods
Mostly true Prediction 28 Sep 2007 Carbon capture and sequestration for coal plants will work technically. Prediction · 28 Sep 2007 Technology
Mostly true Factual 28 Sep 2007 For the first 15 years solar photovoltaic cells were built, they took far more energy to produce than was ever got out of them in their lifetime. Factual · 28 Sep 2007 Technology
Back to the list

Vinod Khosla

Open its page

Factual Biosecurity

“It also suggests 10-plus potential treatments, many of which are already FDA approved.”

Vinod Khosla, on X 4 September 2020 Post by @vkhosla on X, 2020-09-04 (X)

The bradykinin hypothesis for Covid-19 suggests 10-plus potential treatments, many of which are already FDA approved.

Mostly true True in substance, wrong in a detail.

The second judge would not resolve this claim; the verdict shown is the first judge's.

What would count as true or false

Judge as of September 2020 against the bradykinin hypothesis literature (Garvin et al., eLife 2020) and the coverage of it at the time. True: these sources set out about ten or more candidate treatments, and many of them (several, not just one or two) were drugs already approved by the FDA, for any indication. Mostly true: the count was slightly under ten (about 7–9), or only a few of the candidates were FDA approved. Mixed: the hypothesis named only a handful of treatments, with some approved. Mostly false: it named only a few candidates and at most one approved drug. False: it proposed no specific treatments, or none of the named ones was FDA approved.

Evidence

  1. A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm eLife (via PubMed Central) · 7 July 2020
    “Several interventional points (most of them already FDA-approved pharmaceuticals) could be explored with the goal of increasing ACE, decreasing BK, or blocking BK2 receptors (Table 1).”
  2. A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm eLife (via PubMed Central) · 7 July 2020
    “Hymecromone (4-methylumbelliferone) is approved for use in Asia and Europe for the treatment of biliary spasm.”
  3. Bradykinin Hypothesis: Potential Explanation for COVID-19 Pharmaceutical Intelligence (Aviva Lev-Ari) · 8 September 2020
    “repurpose existing FDA approved drugs such as Danazol, Stanasolol, Icatibant, Ecallantide, Berinert, Cynryze, Haegarda, etc..”

Reasoning

The Garvin et al. eLife paper proposes several intervention points, "most of them already FDA-approved pharmaceuticals" (E1). It also names hymecromone, which it describes as approved for use in Asia and Europe, without saying whether it is FDA approved (E2). Coverage from September 2020 lists seven named drugs it calls FDA approved, followed by "etc." (E3). Together these show at least eight named candidates, many of them FDA approved. The quoted evidence does not confirm ten or more, because the paper's Table 1 is not in the fetched text, so the count is only shown in the 7–9 range.

Cite this claim

Vinod Khosla, “The bradykinin hypothesis for Covid-19 suggests 10-plus potential treatments, many of which are already FDA approved.” (said 4 September 2020). Verdict: mostly true. Reliability API, claim c_95e1d691387f, method 0.1.0+c876030c. https://epistacklabs.com/claims/c_95e1d691387f

Claims without a verdict

Is a verdict here wrong, or do you speak for Vinod Khosla? Reply on the claim's own page, with the form at its foot (how replies work). Verdicts are made automatically; how verdicts and scores are made.